Board Meeting Details

The Board meeting commenced at 10:30 a.m. IST and concluded at 11:30 a.m. IST at the Registered Office of the Company.

Key Matters Approved

1. Financial Results Approval

The Board considered and approved:

  • Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026
  • Prepared in compliance with Indian Accounting Standards (IND AS)
  • Includes Limited Review Report of the Auditor
2. Share Swap Authorization

The Board authorized Mr. Punitkumar Rasadia (Chairman & Managing Director) and/or Mr. Meet Vachhani (Whole Time Director) to:

  • Enter into share swap arrangement with shareholders of Apiqo Organics Private Limited (AOPL) and Bizotic LifeScience Private Limited (BLPL)
  • Acquire 32.52% shareholding in AOPL
  • Acquire 43.33% shareholding in BLPL
  • Make both entities wholly owned subsidiaries
  • Consideration: Issuance and allotment of fresh equity shares on preferential basis for consideration other than cash

Standalone Financial Results (Quarter Ended June 30, 2026)

Income Statement (₹ in Lakhs)
  • Revenue From Operations: ₹3,097.56
  • Other Income: ₹5.96
  • Total Income: ₹3,103.52
  • Cost of materials consumed: ₹2,959.48
  • Changes in inventories: (₹789.16)
  • Employee benefits expense: ₹152.07
  • Finance costs: ₹118.29
  • Depreciation and amortization: ₹65.79
  • Other expenses: ₹294.04
  • Total expenses: ₹4,282.32
  • Profit before tax: ₹1,261.15
  • Current tax: ₹152.39
  • Deferred tax: ₹133.41
  • Total tax expense: ₹285.80
  • Profit after tax: ₹975.35
  • Other Comprehensive Income: (₹1.73)
  • Total Comprehensive Income: ₹973.62
Comparative Figures (Quarter Ended)
  • March 31, 2026: Revenue ₹5,542.22, PAT ₹479.71
  • June 30, 2025: Revenue ₹3,329.72, PAT ₹354.69

Consolidated Financial Results (Quarter Ended June 30, 2026)

Income Statement (₹ in Lakhs)
  • Revenue From Operations: ₹8,756.27
  • Other Income: ₹5.96
  • Total Income: ₹8,762.23
  • Cost of materials consumed: ₹7,303.61
  • Changes in inventories: (₹695.55)
  • Employee benefits expense: ₹194.65
  • Finance costs: ₹92.46
  • Depreciation and amortization: ₹106.60
  • Other expenses: ₹394.47
  • Total expenses: ₹7,396.24
  • Profit before tax: ₹1,365.99
  • Current tax: ₹349.30
  • Deferred tax: ₹188.55
  • Total tax expense: ₹537.85
  • Profit after tax: ₹828.14
  • Attributable to owners: ₹666.21
  • Attributable to non-controlling interests: ₹161.93
  • Other Comprehensive Income: (₹1.89)
  • Total Comprehensive Income: ₹826.25
  • Attributable to owners: ₹664.32
  • Attributable to non-controlling interests: ₹161.93
Capital Structure
  • Paid-Up Equity Share Capital: ₹1,063,030,000.00
  • Face Value per share: ₹2.00
  • Earnings per share (Basic): ₹0.16
Comparative Figures (Quarter Ended)
  • March 31, 2026: Revenue ₹5,088.91, PAT ₹1,107.19, EPS ₹0.23
  • June 30, 2025: Revenue ₹3,329.72, PAT ₹354.69, EPS ₹0.09

Subsidiary Information

The consolidated financial results include:

  • Anlon Healthcare Limited (Holding Company)
  • Apiqo Organics Private Limited (Subsidiary)
  • Bizotic Lifescience Private Limited (Subsidiary)
  • Remember India Health Links Private Limited (Subsidiary)

Subsidiaries contributed:

  • Total revenue (before consolidation): ₹5,707.14 lakhs
  • Total net PAT (before consolidation): ₹348.42 lakhs
  • Total comprehensive profit (before consolidation): ₹348.26 lakhs

Investor Complaints

No investor complaints received during Q1 FY27. No pending complaints as of quarter end.

IPO Proceeds Utilization Certificate

Statutory auditor RVD & Co. certified utilization of IPO proceeds:

  • Issue period: August 26, 2025 to August 29, 2025
  • Issue type: Public issue of equity shares
  • Issue size: ₹121.03 crore
  • Status: All funds fully utilized as per offer document
  • No deviations from objects disclosed in prospectus
  • No unutilized balance as of June 30, 2026
Utilization Details (₹ in Lakhs)

1. Funding capital expenditure for manufacturing facility expansion: ₹3,071.95 (100% utilized)

2. Repayment of outstanding secured borrowing: ₹500.00 (100% utilized)

3. Funding working capital requirement: ₹4,315.00 (100% utilized)

4. Offer expenses: ₹1,428.66 (100% utilized)

5. General corporate purposes: ₹2,787.39 (100% utilized)

Auditor Reports

Independent auditor RVD & Co. issued unqualified review reports for both standalone and consolidated financial results, confirming:

  • Preparation in accordance with Ind AS 34 and SEBI Listing Regulations
  • No material misstatements identified
  • Compliance with Regulation 33 requirements